Everything you need to win GSK and Chongqing Zhifei Biological Products — in one platform.
Who to reach, what to say, and why now on GSK and Chongqing Zhifei Biological Products — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on GSK and Chongqing Zhifei Biological Products — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
GSK and Zhifei expand partnership for shingles and RSV vaccines in China
Dec 06, 2024•over 1 year ago
Contract Type
partnership
ChinaBiotechnology
Description
GSK has expanded its partnership with Chongqing Zhifei Biological Products in mainland China, allowing Zhifei to purchase volumes of GSK’s shingles vaccine Shingrix worth up to £2.3bn over the coming six years. In addition, Zhifei will collaborate with GSK on the commercialisation of a respiratory syncytial virus (RSV) vaccine over an initial period of 10 years.
Company Information
Company
GSK and Chongqing Zhifei Biological Products
Location
China
About
GSK is a British drugmaker with a focus on developing innovative vaccines and medicines. Chongqing Zhifei Biological Products is a Chinese biotechnology company with an extensive network of vaccination points across China.
Predictive Intelligence
Strategic
ML-powered predictions for GSK and Chongqing Zhifei Biological Products's next move
ChinaBiotechnology